Gilead Sees Large Insider Stock Sale Into Debt Offering
A Gilead Sciences bond offering and a key insider stock sale netting over $14 million should be considered by investors.
A Gilead Sciences bond offering and a key insider stock sale netting over $14 million should be considered by investors.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies, such as Ebola-vaccine companies.
A new report from Cowen makes the case that a blood test that detects evidence of cancer in the circulation could soon replace the older more traditional biopsy methods.
Dendreon has committed the ultimate sin by filing for bankruptcy protection.
Humana reported disappointing third-quarter 2014 results before markets opened Friday morning.
Inotek Pharmaceuticals Corp. has filed with the U.S. Securities and Exchange Commission (SEC) for an initial public offering.
Oppenheimer has released its list of potential post-election winners in the medical device industry.
Credit Suisse released its first edition of the "Credit Suisse Biosimilars 101" series of notes, offering analysis and impact of biosimilars.
MannKind reported its third-quarter financial results on Monday morning.
The FDA gave Geron some good news Monday morning when it removed the clinical hold on the its investigational new drug application for imetelstat.
In the wake of a reported net loss on disappointing sales of its lead product, Aegerion Pharmaceuticals shares lost a third of their value.
Lakeland.comLakeland Industries Inc. (NASDAQ: LAKE) gave an update Thursday on its business activity in the wake of the Ebola crisis. Globally the two top-selling protective suits for Lakeland are the ChemMax and the MicroMax.…
A new research note from Cowen focuses on health care companies that have released earnings and offer investors reasons to own the stocks.
The analysts at Piper Jaffray are very positive on four top specialty pharmaceutical stocks with potential for a strong fourth-quarter rally in their shares.
Gilead Sciences reported disappointing third-quarter results after the market close on Monday.